2025-08-31-accounts - European Diabetology

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Charity Registration No. 1156725

Company Registration No. 08652560 (England and Wales)

EUROPEAN DIABETOLOGY

REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2025

EUROPEAN DIABETOLOGY

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees and Management Committee	Prof B Ahren
	Ms E Doble (appointed 1 September 2025)
	Prof R Loos
	Prof M Malecki (appointed 4 February 2025)
	Prof E Pearson
	Dr F Rutters (appointed 18 September 2024)
	Prof M Solimena (appointed 1 September 2025)
Secretary	Ms M L Preston
Charity number	1156725
Company number	08652560
Principal address	Learning & Research Building
	Southmead Hospital
	Westbury-On-Trym
	Bristol
	BS10 5NB
Registered office	RSM
	2nd Floor
	One The Square
	Temple Quay
	Bristol
	BS1 6DG
Independent examiner	Kerry Gallagher FCA DChA
	RSM UK Tax and Accounting Limited
	Chartered Accountants
	Davidson House
	Reading
	Berkshire
	RG1 3EU
Bankers	Barclays Bank Plc
	15 Queen Square
	Bristol
	BS1 4NP

EUROPEAN DIABETOLOGY

TRUSTEES REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 AUGUST 2025

The Trustees present their report and financial statements for the year ended 31 August 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Companies Act 2006 and “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) second edition - October 2019.

Objectives and activities

The Charity's objects are specifically restricted to advancing the education of the public in general (and particularly among scientists and healthcare professionals) on the subject of diabetology. This is to be achieved by, but not limited to, the promotion of research for the public benefit in all aspects of that subject and to publish the useful results. In this year, the Charity continued to support the European Association for the Study of Diabetes’ (EASD) Early Career Academy with a grant, enabling 25 applicants to take a place on its new Early Career Mentorship programme. It also took an active role in the creation of Diabetologia’s sister journal Metabologia and negotiating the contract with publisher Springer Nature, with the aim of best serving its authors and readership in view of the Charity's objects. The expanded scope of the new journal offers increased opportunity for the Charity to communicate about further fields and their relation to diabetology. In addition, they supported the IDS conference with a grant towards its Young Investigator Travel Awards aimed to motivate young scientists to send in abstracts.

The Trustees confirm that they have complied with the duty in section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

The Trustees have also paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

Achievements and performance

The Charity has supported the advancement of education on the subject of diabetes by supporting the publication of the journal Diabetologia, in particular by funding their editorial activities.

The Trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the aims and objectives and in planning the future activities of the Charity.

Financial review

Total income for the financial year was £768,833 (2024: £579,424). Outgoings and other gains/losses for the same year were £541,902 (2024: £234,946) creating an annual surplus of £226,931 (2024: 344,478). Total funds carried forward into the new financial year are £1,741,824 (2024: £1,514,893).

Reserves policy

The Trustees examined the requirements for free reserves in November 2023 and agreed that, given the nature of the work and current outstanding decisions on expenditure, this should be approximately £450,000. This includes the equivalent of six months’ running costs of Diabetologia to allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer Nature. It also provides a contingency against changes in the terms agreed with the University of Bristol in relation to the hosting of Diabetologia. It also gives adequate working capital to support quality improvement in Diabetologia. Therefore, the Trustees have decided to earmark £450,000 to a separate designated fund for clarity within the financial statements. The reserves as of 31 August 2025 are £1,741,824 (2024: £1,514,893).

Investment policy

During the year, the Charity maintained a multi-asset fund with Schroders. As the Charity’s investment advisors, they are instructed to invest to maximise total return within the constraints of a lower level risk portfolio. The investment brief is broadly defined, but investments in companies that have positive social, environment and ethical considerations are held or pursued.

EUROPEAN DIABETOLOGY

TRUSTEES REPORT (INCLUDING DIRECTORS' REPORT)(CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

Risk management

The Trustees consider the main risk to the future of the Charity to be the funding provided, without this the Charity would not be able to provide support for the publication of the journals Diabetologia and Metabologia. The Trustees have publishing agreements in place with Springer Nature to receive royalties annually and work closely with EASD and the journals’ Editors-in-Chief to ensure the financial forecast is secured.

The Charity plans to continue supporting the activities of Diabetologia and also now Metabologia, and to fund new initiatives that serve to develop diabetes education in the scientific, medical and wider community as well as improve the quality of the journals’ output and marketing, when finances permit.

Structure, governance and management

European Diabetology is a company limited by guarantee (Company Registration No. 08652560) with charitable status (Charity Registration No. 1156725). The company was registered with Companies House on 15 August 2013. The governing document of the organisation is its Memorandum and Articles of Association dated August 2013 and modified in March 2014. The registered office is RSM, 2nd Floor, One The Square, Temple Quay, Bristol BS1 6DG.

The Trustees, who are also the directors for the purposes of company law, who held office during the year and up to the date of signature of the financial statements were as follows:

Prof E Pearson (Chair) Prof F Rutters (Vice Chair) (appointed 18 September 2024) Prof B Ahren (Treasurer) Ms E Doble (appointed 1 September 2025) Prof K Gillespie (resigned 26 February 2025) Prof R Loos Prof M Malecki (appointed 4 February 2025) Ms S Tweddell (resigned 16 November 2025)

The day-to-day management of the Charity is carried out by the Trustees, who are appointed by a resolution of the Trustees from a candidate, or candidates, nominated in writing by the European Association for the Study of Diabetes. The number of Trustees shall not be less than three but shall not be subject to any maximum. The Trustees hold office for three years and are then eligible for reappointment for a further three years. The induction process for any newly appointed Trustee comprises an initial meeting with the Chairman and the Board, followed by a series of short meetings regarding powers and responsibilities of the Trustee Board.

Members' liability

Each member of the charitable company undertakes to contribute to the assets of the charitable company in the event of it being wound up while they are a member, or within one year after they cease to be a member, such amount as may be required, not exceeding £1, for the debts and liabilities contracted before they ceased to be a member.

Related party transactions

In its commitment to advance education regarding diabetes, European Diabetology is primarily supportive of the journals Diabetologia and Metabologia and their associated society, the European Association for the Study of Diabetes (EASD). This may be in the form of financial grants but also professional benevolence. EASD is the Charity’s primary beneficiary and the Charity remains open to assisting its various outreach initiatives.

EUROPEAN DIABETOLOGY

TRUSTEES REPORT (INCLUDING DIRECTORS' REPORT)(CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies’ exemption.

The Trustees report was approved by the Board of Trustees.

Bo Ahrén

.............................. Prof B Ahren Trustee

Dated: .........................26/05/26

EUROPEAN DIABETOLOGY

STATEMENT OF TRUSTEES RESPONSIBILITIES FOR THE YEAR ENDED 31 AUGUST 2025

The Trustees (who are also the directors of European Diabetology for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

select suitable accounting policies and then apply them consistently;
observe the methods and principles in the Charities SORP;
make judgments and accounting estimates that are reasonable and prudent;
state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

EUROPEAN DIABETOLOGY

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF EUROPEAN DIABETOLOGY

I report on the financial statements of the Charity for the year ended 31 August 2025, which are set out on pages 6 to 15.

Respective responsibilities of Trustees and examiner

As the Trustees of the Charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (‘the 2011 Act’).

I report in respect of my examination of the Charity’s financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145 (5)(b) of the 2011 Act.

An independent examination does not involve gathering all the evidence that would be required in an audit and consequently does not cover all the matters that an auditor considers in giving their opinion on the financial statements. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I express no opinion as to whether the financial statements present a ‘true and fair view’ and my report is limited to those specific matters set out in the independent examiner’s statement.

Independent examiner's statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act.

I confirm that I am qualified to undertake the examination because I am a member of The Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
the financial statements do not accord with those records; or
the financial statements do not comply with the applicable requirements concerning the form and content of financial statements set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the financial statements give a ‘true and fair view’ which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Kerry Gallagher

Kerry Gallagher FCA DChA

The Institure of Chartered Accountants in England and Wales

On behalf of RSM UK Tax and Accounting Limited Chartered Accountants Davidson House Forbury Square Reading Berkshire RG1 3EU

26/05/26 Dated: .........................

EUROPEAN DIABETOLOGY

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 AUGUST 2025

		Unrestricted Unrestricted	Unrestricted Unrestricted
		funds	funds
		2025	2024
	Notes	£	£
Income from:
Charitable activities	2	728,645	554,331
Investments	3	40,188	25,093
Total income		768,833	579,424
Expenditure on:
Charitable activities	4	577,015	273,994
Net income before gains/(losses)		191,818	305,430
Net gains on investments	9	44,644	39,818
Other losses	10	(9,531)	(770)
Net movement in funds		226,931	344,478
Total funds brought forward		1,514,893	1,170,415
Total funds carried forward		1,741,824	1,514,893

All income and expenditure derives from continuing activities and was unrestricted in the current and previous year.

Company Registration No. 08652560

EUROPEAN DIABETOLOGY

BALANCE SHEET

AS AT 31 AUGUST 2025

Notes Fixed assets Investments 11 Current assets Debtors 12 Investments 13 Cash at bank and in hand Creditors: amounts falling due within one year 14 Net current assets Total assets less current liabilities Income funds Designated funds 16 Unrestricted funds	2025 £ £ 629,123 232,293 300,000 813,639 1,345,932 (233,231) 1,112,701 1,741,824 450,000 1,291,824 1,741,824	2024 £ £ 563,166 302 - 1,118,284 1,118,586 (166,859) 951,727 1,514,893 450,000 1,064,893 1,514,893	2024 £ £ 563,166 302 - 1,118,284 1,118,586 (166,859) 951,727 1,514,893 450,000 1,064,893 1,514,893
			1,514,893

			1,514,893

The charitable company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006 (the Act) for the year ended 31 August 2025 and its members have not required the charitable company to have an audit of its financial statements for the period in question in accordance with section 476 of the Act.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of the financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the officers on ............ and signed on their 26/05/26 behalf by:

Bo Ahrén

..............................

Prof B Ahren Trustee

EUROPEAN DIABETOLOGY

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 AUGUST 2025

Notes Cash flows from operating activities Cash (absorbed by)/generated from operations 18 Investing activities Interest received Net cash generated from investing activities Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year	2025 £ 18,875	£ (323,520) 18,875 (304,645) 1,118,284 813,639	2024 £ 7,985	£ 177,649 7,985 185,634 932,650
				1,118,284

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies

Charity information

European Diabetology (the Charity) is a private company limited by guarantee incorporated in England and Wales. The registered office is RSM, 2nd Floor, One The Square, Temple Quay, Bristol BS1 6DG. The Charity is registered in England and Wales by the Charity Commission (Charity Registration No. 1156725).

Accounting convention

The financial statements have been prepared in accordance with the Charity's governing document, the Companies Act 2006 and “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2019).

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in Sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The Charity constitutes a public benefit entity as defined by FRS102.

The financial statements have been prepared under the historical cost convention with the exception of fixed asset investments which are held at fair value. The principal accounting policies adopted are set out below.

Going concern

The Trustees have reviewed the expected cash outflows for the Charity against expected cash inflows and assets held for twelve months from the approval of these financial statements. The Trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern, and therefore have concluded that it is appropriate to use the going concern basis in the preparation of these financial statements.

Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes. Designated funds are set aside by the Trustees to be spent on specific purposes at their own discretion. The designated funds currently in the financial statements relate to approximately six months' running costs of Diabetologia.

Income

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Investment income is accounted for in the accounting period in which it is receivable.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the Charity to the expenditure. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category.

Charitable expenditure comprises costs incurred by the Charity in delivery of its activities and objectives. It includes both costs directly attributable to activities and indirect costs necessary to support them.

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies (Continued)

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity and include independent examination fees and costs linked to the strategic management of the Charity.

Gains and losses

All gains and losses are taken to the statement of financial activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year.

Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities,

Investments

Investments are a form of basic financial instrument and are initially measured at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

The market value of investments held in the portfolios are represented within unrestricted funds and the income portfolio is included within the unrestricted distribution fund accordingly.

Financial instruments

The Charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade debtors and other debtors, cash on deposit and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest rate method.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Charity after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade creditors and other creditors are initially recognised at transaction price.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity’s contractual obligations expire or are discharged or cancelled.

10 -

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

1 Accounting policies (Continued)

Taxation

The Charity meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Charity is partially exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

Foreign exchange

Transactions in currencies other than Sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each balance sheet date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the balance sheet date. Gains and losses arising on translation are included in net income for the year.

2 Charitable activities

	2025	2024
	£	£
Promotion of medical research	728,645	554,331

During the current and prior year, all income from charitable activities was received from markets outside the UK but within Europe.

3 Investments

Dividend income Interest receivable	2025 £ 21,313 18,875 40,188	2024 £ 17,108 7,985
		25,093

4 Charitable activities

Promotion of medical research Grant funding of activities (see note 5) Share of support costs (see note 6) Share of governance costs (see note 6) Analysis by fund Unrestricted funds - general	2025 £ 528,059 29,368 15,469 4,119 577,015 577,015	2024 £ 259,372 - 12,372 2,250
		273,994
		273,994

11 -

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

5 Grants payable

Grants to institutions: EASD Academy Network Programme KU Leven - 20th IDS Congress	2025 £ 21,028 8,340 29,368	2024 £ - -
		-

6 Support costs

Support costs Governance costs £ £ Accountancy costs 11,103 - Travel and subsistence 2,381 - Computer costs 30 - Bank charges 744 - Office costs 9 - Insurance 678 - Other costs 524 - Legal and professional - 748 Independent examination fees - 3,371 15,469 4,119 Analysed between Charitable activities 15,469 4,119	2025 £ 11,103 2,381 30 744 9 678 524 748 3,371 19,588 19,588	2024 Basis of allocation £ 8,033 1,698 2,150 491 - - - - Governance 2,250 Governance 14,622 14,622

7 Trustees

The Trustees neither received nor waived any emoluments from the Charity during the year (2024: £Nil). Trustees received payments of £563 (2024: £1,698) in respect of travel costs reimbursed. The Trustees are considered to be key management personnel of the Charity.

8 Employees

European Diabetology has no employees. The personnel are employed by the University of Bristol, who recharge these costs to the Charity.

9 Net gains/(losses) on investments

		2025	2024
		£	£
Unrealised gains on investments (note	11)	44,644	39,818

12 -

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

10 Other gains or losses Foreign exchange losses 11 Fixed asset investments Movement in fixed asset investments Market value brought forward Additions Valuation changes Market value carried forward The Charity holds investments in a multi-asset fund with Schroders. 12 Debtors Amounts falling due within one year: Trade debtors Other debtors Prepayments and accrued income 13 Current asset investments Cash on deposit		2025 £ 9,531 2025 £ 563,166 21,313 44,644 629,123	2025 £ 9,531 2025 £ 563,166 21,313 44,644 629,123	2024 £ 770
				2024 £ 506,240 17,108 39,818
				563,166
				2024 £ - 136 166

	2025 £ 103,864 1,514 126,915 232,293 2025 £ 300,000
				302
				2024 £ -

13 -

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

14 Creditors: amounts falling due within one year

Creditors: amounts falling due within one year
Trade creditors Accruals and deferred income	2025 £ 5,410 227,821 233,231	2024 £ - 166,859
		166,859

Included in the above is £158,826 (2024: £159,515) of deferred income relating to the remaining amount due from the publishing agreement. All deferred income from 2024 has been released to the statement of financial activities in the current year.

15	Financial instruments	2025	2024
		£	£
	Equity instruments measured at fair value through profit or loss	629,123	563,166

16 Movement in funds

The income funds of the Charity include the following designated funds which have been set aside out of unrestricted funds by the Trustees for specific purposes:

		Movement in funds	Movement in funds
	Balance at 1	Incoming	Resources Revaluations,	Balance at 31
	September	resources	expended gains and	August 2025
	2024		losses
	£	£	£ £	£
Unrestricted funds	1,064,893	768,833	(577,015) 35,113	1,291,824
Designated funds	450,000	-	- -	450,000
	1,514,893	768,833	(577,015) 35,113	1,741,824
		Movement in funds
	Balance at 1	Incoming	Resources Revaluations,	Balance at 31
	September	resources	expended gains and	August 2024
	2023		losses
	£	£	£ £	£
Unrestricted funds	720,415	579,424	(274,764) 39,818	1,064,893
Designated funds	450,000	-	- -	450,000
	1,170,415	579,424	(274,764) 39,818	1,514,893

No restricted funds were received in the year.

The Trustees have decided to designate approximately six months' running costs of Diabetologia. This would allow for an orderly wind-down of the activities of the journal in the event of interruption of income from Springer Nature. The funds remain unrestricted and can be spent at the Trustees' discretion.

14 -

EUROPEAN DIABETOLOGY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 AUGUST 2025

17 Analysis of net assets between funds Fund balances at 31 August 2025 are represented by: Investments Current assets Creditors: amounts falling due within 1 year 18 Cash generated from operations Surplus for the year Adjustments for: Investment income recognised in statement of financial activities Fair value gains and losses on investments Movements in working capital: Increase in cash on deposit Increase in debtors Increase/(decrease) in creditors Cash (absorbed by)/generated from operations	2025 £ 629,123 1,345,932 (233,231) 1,741,824 2025 £ 226,931 (40,188) (44,644) (300,000) (231,991) 66,372 (323,520)	2024 £ 563,166 1,118,586 (166,858)
		1,514,894
		2024 £ 344,478 (25,093) (39,818) - (8) (101,910)
		177,649

19 Related party transactions

The University of Bristol are the employer of a Trustee of European Diabetology. Expenses of £527,499 were incurred in relation to the University of Bristol during the year (2024: £237,576). No interest is due if payment is received 30 days from the invoice date.

The following balance sheet items relate to amounts due to the University of Bristol:

Accruals Prepayments	2025 £ 61,872 123,745 185,617	2024 £ - -
		-

15 -